Recent 8-K filings for PAVM

• May 15, 2026, 8:05 AM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests

  GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).

• March 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M

  PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.

• March 27, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 5.03item 9.01 ◈ Governance Changes

  PAVmed stockholders approve stock issuance, charter amendment, and equity plan increase at special meeting

  Approved issuance of shares upon conversion of 60,000 Series D Preferred shares and shares under Convertible Note (640,946 for, 72,380 against).

• February 4, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01item 1.02item 2.03item 3.02item 3.03item 5.03item 7.01item 9.01 ◈ Material Agreements ×2

  PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities

  Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.

• January 23, 2026, 6:59 PM ET regulatory materiality 0.45 positive item 8.01item 9.01

  PAVmed regains Nasdaq $1 minimum bid price compliance

  Received Nasdaq notice on Jan 21, 2026 that it regained compliance with Listing Rule 5550(a)(2).

• December 30, 2025, 6:59 PM ET other material materiality 0.65 neutral item 3.03item 5.03item 7.01item 2.02item 9.01 ◈ Governance Changes

  PAVmed announces 1-for-30 reverse stock split effective Jan 2, 2026 to regain Nasdaq compliance

  1-for-30 reverse split effective Jan 2, 2026; authorized shares reduced from 250M to 25M.

• December 5, 2025, 6:59 PM ET other material materiality 0.60 neutral item 5.07item 9.01

  PAVmed shareholders approve reverse stock split (1:10–1:30) and authorized share reduction to 25M

  Stockholders approved reverse split (ratio 1:10–1:30, board to decide) and authorized share reduction from 250M to 25M.

• November 13, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support

  GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.

• September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  PAVmed subsidiary Lucid Diagnostics closes $28.75M stock offering at $1.00/share

  Lucid Diagnostics sold 28.75M shares at $1.00 each via underwritten offering.

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 7.01item 9.01

  PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests

  GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).

• July 30, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 8.01item 9.01

  PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price

  Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.

• June 24, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  PAVmed subsidiary Veris Health raises $2.5M in equity and warrant offering

  Veris sold 1,785,714 common shares and warrants at $1.40 per share unit.

• June 18, 2025, 7:59 PM ET other material materiality 0.35 neutral item 5.02item 5.07item 9.01

  PAVmed shareholders re-elect directors, approve equity plan increase and stock issuance at annual meeting

  Re-elected Lishan Aklog (7.15M for, 2.08M withheld) and Michael Glennon (7.22M for, 2.01M withheld) as Class C directors.

• May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M

  GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).

• April 25, 2025, 7:59 PM ET other material materiality 0.50 neutral item 4.01item 9.01

  PAVmed appoints CBIZ CPAs as new auditor after Marcum acquisition; no disagreements

  Marcum resigned as auditor on April 23, 2025 following its attest business acquisition by CBIZ CPAs.

• April 17, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01

  PAVmed enters $2.88M at-the-market equity offering agreement with Maxim Group

  ATM offering up to $2,880,000 of common stock under shelf registration effective April 15, 2025.

• April 11, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  PAVmed subsidiary Lucid Diagnostics closes 14.4M share offering raising ~$16.1M net

  Lucid Diagnostics closed sale of 14,375,000 shares at $1.20 each, including full exercise of underwriters' option.

• March 25, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured

  GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.

• March 10, 2025, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  PAVmed subsidiary Lucid Diagnostics closes ~$15.3M equity offering at $1.10/share

  Lucid Diagnostics sold 13.9M shares at $1.10 each, gross proceeds ~$15.3M.

• February 21, 2025, 6:59 PM ET other material materiality 0.70 neutral item 3.02item 9.01

  PAVmed raises $2.37M via PIPE of common stock and pre-funded warrants with Veris subsidiary shares

  Sale of 2,574,350 shares and 756,734 pre-funded warrants at $0.7115/unit; Veris issues 677,143 shares to investors.

• February 18, 2025, 6:59 PM ET regulatory materiality 0.35 neutral item 8.01item 9.01

  PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring

  Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).

• January 24, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01item 3.02item 3.03item 9.01 ◈ Listing & Compliance Notices

  PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares

  Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.

• January 21, 2025, 6:59 PM ET other material materiality 0.75 neutral item 3.01item 3.02item 3.03item 5.03item 8.01item 9.01

  PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance

  Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.

• January 15, 2025, 6:59 PM ET other material materiality 0.65 negative item 5.03item 5.07item 9.01

  PAVmed stockholders approve 4x increase in authorized shares to 250M and Series C Preferred issuance

  Stockholders approved amending the certificate of incorporation to increase authorized common shares from 50M to 250M, effective Jan 15, 2025.

• November 29, 2024, 6:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 3.03item 9.01

  PAVmed sub Lucid closes $21.95M convertible note placement; net $18.3M

  Lucid Diagnostics (PAVmed sub) closed $21.95M in Senior Secured Convertible Notes to accredited investors.

• November 21, 2024, 6:59 PM ET debt materiality 0.90 negative item 1.01item 3.02item 3.03item 9.01

  PAVmed exchanges $22.3M convertible notes for Series C Preferred Stock and enters separate $2.65M purchase

  Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.

• November 14, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 7.01item 9.01

  PAVmed reports Q3 GAAP net income $64.3M driven by deconsolidation; Lucid EsoGuard revenue record $1.2M

  Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.

• September 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.01item 5.02item 3.01item 7.01item 9.01 ◈ executive_change ×3

  PAVmed deconsolidates Lucid Diagnostics, expects ~$70M gain; faces Nasdaq delisting, appoints new director

  Deconsolidated Lucid from financials; expects ~$70M non-cash gain in Q3 2024.

• August 13, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)

  Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).

• June 20, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  PAVmed Inc. stockholders re-elect directors and ratify auditor at 2024 annual meeting

  Approximately 58.5% of outstanding shares were represented at the June 20, 2024 annual meeting.

• May 14, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M

  GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).

• May 7, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.03item 3.02item 5.03item 9.01 ◈ Material Agreements

  PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering

  Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.

• May 1, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  PAVmed subsidiary Veris Health signs MOU with Ohio State cancer center for pilot of Veris Cancer Care Platform

  Veris and OSUCCC-James signed MOU to pilot the Veris Cancer Care Platform for cancer patients.

• April 26, 2024, 7:59 PM ET debt materiality 0.40 neutral item 1.01item 9.01

  PAVmed extends $2M fee payment deadline on convertible notes to June 15, 2024

  Letter agreement extends due date for $2,000,000 fee from April 25, 2024 to June 15, 2024.

• March 14, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 3.03item 9.01 ◈ Material Agreements

  PAVmed extends senior secured note maturities to 2025; pays $2M for covenant waiver

  April 2022 Note maturity extended to April 4, 2025; September 2022 Note to September 8, 2025.

• March 14, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.03item 3.02item 9.01 ◈ Material Agreements ×3

  PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange

  Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

5 positive 7 negative 24 neutral

source · PAVM on sec.gov